ReviewCurrent atherosclerosis reports2019
Anticoagulation Resumption After Stroke from Atrial Fibrillation.
Review in Current atherosclerosis reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anticoagulation Timing After Stroke in Atrial Fibrillation: Evidence from a Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke: a real-world study.Journal of neurology · 2023Trial
- Anticoagulation therapy after reperfusion treatment for acute ischemic stroke with non-valvular atrial fibrillation: a multicenter retrospective study.Scientific reports · 2025Article
- Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage.European journal of medical research · 2024Review
- Current and Emerging Endovascular and Neurocritical Care Management Strategies in Large-Core Ischemic Stroke.Journal of clinical medicine · 2023Review
- Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.Current neurology and neuroscience reports · 2023Review
- Hemorrhagic Conversion of Acute Ischemic Stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Anticoagulation and Stroke.Arquivos de neuro-psiquiatria · 2022Article
- Early anticoagulation in atrial fibrillation-related acute ischaemic stroke: efficacy and safety profile.Journal of neurology · 2022Article
- Acute Stroke and Atrial Fibrillation: Risk of Incorrect NOAC Dosage When Estimating Renal Function From Plasma Creatinine Only.Frontiers in neurology · 2022Article
- Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study.European stroke journal · 2021Article
- Article
- Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk.Annals of neurology · 2020Article
- Successful Mechanical Thrombectomy of Bilateral Middle Cerebral Artery Occlusions Following Apixaban Discontinuation.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this paper is to review literature on the topic of anticoagulation resumption after stroke from atrial fibrillation. Following ischemic stroke, the average annual risk of recurrent stroke in a patient with a CHADS2 score of 9 is 12.2%%, translating to an average daily risk of 0.03%%. Oral anticoagulant therapy provides a 75% relative risk reduction. However, in the 2-week period immediately following an acute stroke, this daily risk appears to be elevated. The same period is associated with an increased risk of hemorrhagic transformation of ischemic stroke due to reperfusion, impaired autoregulation, and disruption of the blood-brain barrier. Use of thrombolytics and anticoagulants, baseline infarct size, presence of microhemorrhages, and evidence of hemorrhagic transformation further increases the risk of symptomatic hemorrhagic. The decision to resume anticoagulation early after ischemic stroke from atrial fibrillation must carefully balance the risks of hemorrhagic transformation with the risk of recurrent stroke. There are currently 4 trials in progress at present (OPTIMAS, ELAN, TIMING, and START) comparing different anticoagulant resumption protocols after stroke in patients on non-vitamin K oral anticoagulants. There are a number of major limitations of the studies to date on the timing of anticoagulation resumption on stroke in atrial fibrillation. For instance, they do not explicitly account for infarct size, presence/absence of hemorrhagic transformation, recanalization via mechanical thrombectomy, and bleeding diatheses such as liver synthetic dysfunction or thrombocytopenia. These factors are crucial in personalizing a treatment decision to an individual patient.
Indexed as
Identifiers
31111239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.